DALLAS, July 20, 2010 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring GenVec Inc. (Nasdaq:GNVC). The report includes financial, comparative and investment analyses, and recent company news that you need to know to make an educated investment decision.
Our trade alerts and ideas are provided free to investors. Simply use your email address to subscribe with http://www.microstockprofit.com to get the inside track on our next red-hot alert.
The full report is available at: http://www.microstockprofit.com/lp/GNVC
GNVC has been relatively stable recently. This is evidenced by the width of its Bollinger Bands, which are tighter than normal. Additionally, GNVC is trading within its Bollinger Bands. This is a normal condition and suggests that the stock is neither overbought nor oversold relative to the recent price action.
GenVec Inc. (GNVC) is a clinical stage biopharmaceutical company developing gene-based therapeutic drugs and vaccines. Its lead product candidate, TNFerade biologic (TNFerade), is being developed for use in the treatment of cancer. Using GNVC's core adenovector technology, TNFerade stimulates the production of tumor necrosis factor alpha (TNFa), a known anti-tumor protein, in cells of the tumor. In addition to its therapeutic product development programs, GNVC is working with collaborators to develop new applications for its technology through its vaccine development programs. The Company is developing a vaccine in animal health against foot-and-mouth disease and preventative vaccines for malaria, human immunodeficiency virus (HIV), respiratory syncytial virus and Herpes Simplex Virus Type 2 (HSV-2).
Message Board Search for GNVC: http://www.boardcentral.com/boards/GNVC
In the report, the analyst notes:
"Revenue for the first quarter decreased 23% to $2.9 million from $3.8 million in the same period last year. The decrease for the three-month period ended March 31, 2010, is primarily due to decreased revenue associated with GNVC's agreement with the Department of Homeland Security (DHS) for the foot-and-mouth disease (FMD) program of $1.2 million.
"In late March, GNVC said it stopped a study of its cancer drug candidate, TNFerade, after the Company said the drug would not meet trial goals as a treatment for prostate cancer. GNVC said it planned to focus on its vaccine programs and a collaboration with Swiss drugmaker Novartis AG through which it was developing treatments for hearing loss. It said it would review the study data to decide on any future uses for TNFerade."
To read the entire report visit: http://www.microstockprofit.com/lp/GNVC
See what investors are saying about GNVC at penny stock forum
MicroStockProfit.com Disclosure
MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.